Temozolomide is generally effective after several courses of treatment

Temozolomide is an oral alkylating prodrug that delivers methyl groups to the purine bases of DNA (O6-guanine; n7-guanine and N3-adenine). It is often used with radiation therapy as part of the first-line treatment of high-grade gliomas. The main advantages are its high oral bioavailability (almost 100%, although the concentrations found in cerebrospinal fluid are approximately 20% of the plasma concentrations of temozolomide), its lipophilicity and small size giving it the ability to cross the blood-brain barrier.

Conventional treatment of glioblastoma using surgery, radiation, and temozolomide results in a median patient survival of 14.6 months. Furthermore, the drug showed activity not only in brain tumors but also in a variety of solid tumors. The duration of effect and number of treatment sessions will vary depending on individual circumstances. Generally speaking, modozolomide is usually used in consecutive chemotherapy cycles, each cycle is usually 28 days long, with 6 cycles being common. However, in some cases, the course of treatment may be lengthened or shortened. The specific dosage during each cycle will also be adjusted based on patient response and tolerability.

The original drug temozolomide has been launched in China and has entered the scope of Class B medical insurance. Common specificationsThe price of 100mg*1 tablet*5 bags per box may be around 2,000 yuan. The generic drugs of temozolomide marketed overseas are relatively low-priced, and their drug ingredients are basically the same as those of the original drug of temozolomide. For example, the price of a box of 100mg*5 produced by a Bangladeshi pharmaceutical factory may be around a few hundred yuan (the price may fluctuate due to exchange rates).